GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » PB Ratio

Aerovate Therapeutics (Aerovate Therapeutics) PB Ratio : 6.31 (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-17), Aerovate Therapeutics's share price is $20.59. Aerovate Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $3.26. Hence, Aerovate Therapeutics's PB Ratio of today is 6.31.

The historical rank and industry rank for Aerovate Therapeutics's PB Ratio or its related term are showing as below:

AVTE' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 8.13
Current: 6.32

During the past 5 years, Aerovate Therapeutics's highest PB Ratio was 8.13. The lowest was 0.00. And the median was 0.00.

AVTE's PB Ratio is ranked worse than
81.64% of 1318 companies
in the Biotechnology industry
Industry Median: 2.555 vs AVTE: 6.32

During the past 12 months, Aerovate Therapeutics's average Book Value Per Share Growth Rate was -28.40% per year.

Back to Basics: PB Ratio


Aerovate Therapeutics PB Ratio Historical Data

The historical data trend for Aerovate Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerovate Therapeutics PB Ratio Chart

Aerovate Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 1.67 5.71 5.74

Aerovate Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 3.34 2.99 5.74 9.06

Competitive Comparison of Aerovate Therapeutics's PB Ratio

For the Biotechnology subindustry, Aerovate Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerovate Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's PB Ratio falls into.



Aerovate Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aerovate Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=20.59/3.263
=6.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aerovate Therapeutics  (NAS:AVTE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aerovate Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerovate Therapeutics (Aerovate Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
930 Winter Street, Suite M-500, Waltham, MA, USA, 02451
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Executives
Hunter Gillies officer: Chief Medical Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Ralph Niven officer: Chief Development Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Benjamin T Dake officer: See Remarks C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Marinus Verwijs officer: SENIOR VICE PRESIDENT, CMC C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes director, officer: Chief Executive Officer 1365 MAIN STREET, WALTHAM MA 02451
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot officer: Chief Commercial Officer AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George A Eldridge officer: See Remarks C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Maha Katabi director, 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116